Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06390059 | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | PHASE2 | COMPLETED | 84 | — | — | Aug 28, 2023 | Nov 18, 2025 | Apr 30, 2026 | 15 | Czechia, Germany +2 |
Disease control rate (DCR) will be measured by the proportion of patients who had either stable disease (SD) for at least 16 weeks or confirmed partial response (PR) or complete response (CR) according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| TTFields + atezolizumab + gemcitabine and nab-paclitaxel | EXPERIMENTAL | Patients receive TTFields at 150 kHzconcomitant with atezolizumab, gemcitabine and nab-paclitaxel until disease progression or loss of clinical benefit. |
| Name | Type | Description |
|---|---|---|
| Tumor Treating Fields | DEVICE | The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division. TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit. |
| Atezolizumab | DRUG | Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution. Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
| Gemcitabine | DRUG | Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion. Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
| nab-paclitaxel | DRUG | Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion. Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit. |
Inclusion Criteria: 1. Signed Informed Consent Form for the study protocol. 2. 18 years of age and older at the time of signing Informed Consent Form. 3. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1. 4. Histologically or cytologically confirmed de-novo diagnosis of metastatic...